• IMS Health Indonesia

Driving Healthcare Performance in Indonesia

In 2012, IMS Health Indonesia made a significant investment to further improve the quality of sales audits and better align to our clients' needs. Furthermore, IMS Health has put initiatives in place to expand definitions in order to improve panel coverage, reducing the non-panel sector significantly. These sales audits focus on the coverage of different channels such as drugstore, hospital and pharmacy channels.

We have also made in-roads to further enhance our capabilities, such as retail and hospital panels enhancement, further expansion of our electronic data sources, addition of data contributors, and upcoming improvements in our product classification.

The size of the total pharmaceutical market in Indonesia reached US$4.16 billion in 2013, reflecting a 12.9% market growth on the previous year. Based on IMS Market Prognosis, the market is forecasted to grow at a compound annual growth rate (CAGR) of 13.0% (±3.5%) between 2013 and 2018, reaching Rp 89,402 billion by 2018.

Indonesia continues to expand and improve its basic public healthcare services and the private hospital sector is also expanding. From 2014 onwards, the implementation of a National Health Insurance (NHI) system, will help to increase access to healthcare and drive volume growth, mainly for cheaper generics. The use of generics will be encouraged in the public hospital sector, especially after the implementation of the NHI scheme. This coupled with growing pressure on prices and the risk of further controls on branded generics will add to the competition for sales.

In today's highly competitive and complex environment, contact your IMS Health Indonesia representative to gain greater clarity and stay one step ahead of the competition with the valuable insights gained from IMS Health offerings.